Pharmacist Medication Insights: Somapacitan (Sogroya) for Growth Hormone Deficiency

Video

Somapacitan (Sogroya; Novo Nordisk) injection is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

Somapacitan (Sogroya; Novo Nordisk) injection is approved for the replacement of endogenous growth hormone in adults with growth hormone deficiency.

The human growth hormone analogue is administered via subcutaneous injection once weekly.

Somapacitan acts similarly to human growth hormone. After injection, the drug attaches to a protein in the blood called albumin, which allows it remain in the body for longer. This enables weekly administration of Sogroya, which is favorable to the daily dosing of other growth hormone replacement therapies.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.